<i>Iqgap2</i>^<i>-/-</i> colons are characterized by diminished production of IL-6 in response to DSS treatment.

Abstract

<p><b>A.</b> IL-6 (left) and IL-10 (right) mRNA cytokine levels as quantified by qRT-PCR in colons from WT and <i>Iqgap2</i>^<i>-/-</i> mice from the three groups: untreated, treated with DSS, and treated with DSS and allowed to recover for 7 days, N = 3 per group per genotype. The levels of IL-6 mRNA in DSS-treated <i>Iqgap2</i>^<i>-/-</i> colons were beyond the sensitivity of the method used. Data are presented as a transcript fold change relative to actin mRNA transcript levels. <b>B.</b> IF showing reduced IL-6 production (red) in DSS-treated <i>Iqgap2</i>^<i>-/-</i> colons (panel c) compared to DSS-treated WT (panel a). White arrows indicate representative IL-6-positive cells. Panels b and d show corresponding DAPI staining. Magnification is 200 X. Images are representative of N = 3 per genotype. <b>C.</b> Quantification of IF IL-6 positive cells in colons from WT and <i>Iqgap2</i>^<i>-/-</i> mice from the three groups: untreated, treated with DSS, and treated with DSS and allowed to recover for 7 days. Data represent an average of ten randomly selected fields per sample ± SD. N = 3 per genotype/treatment. P-values indicating statistically significant differences are shown. <b>D.</b> IHC for phospho-STAT3(Tyr705) in WT and <i>Iqgap2</i>^<i>-/-</i> colons before and after DSS treatment, N = 5 per group. Representative pSTAT3-positive cells are pointed with black arrows. Magnification is 200 X.</p